Bruton tyrosine kinase inhibitor (BTKi) therapy has revolutionized the treatment of chronic lymphocytic leukemia (CLL) and has also been found to be effective in certain types of B-cell non-Hodgkin’s Lymphoma (NHL) [9]. This evidence concerns the gene IBTK and B-cell chronic lymphocytic leukemia.